en · de · es · fr · pt
cjc-1295-notes.peptides7501.com › Data › Mechanism And Pharmacokinetics — Practical Notes

Mechanism And Pharmacokinetics — Practical Notes

By Editorial Desk · published 2025-08-31 · last reviewed 2025-09-23 · Data

If you have been reading about drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-09-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

Persistence, Stability and Measurement

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Cjc-1295 at a glance

PropertyValueNotes
Target receptorGHRH receptor (GHRHR)Expressed on pituitary somatotrophs
Primary actionStimulates growth hormone releaseAmplifies pulse size
Half-life, albumin-binding formSeveral days as reportedSlow release from albumin complex
Half-life, unmodified analogAbout 30 minutes in animal estimatesCleared by proteases and filtration
Common analytical approachLC-MS/MS for peptide, immunoassay for hormonesMethods answer different questions

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Related pages on this site

Identity and Naming History

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Compound Identity and Development History

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Notes from published material

== External links == Motilin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Nosek TM. "Section 6/6ch2/s6ch2_26". Essentials of Human Physiology. Archived from the original on 2016-03-24.

==== Phenotypic drug discovery ==== Phenotypic drug discovery is a traditional drug discovery method, also known as forward pharmacology or classical pharmacology. It uses the process of phenotypic screening on collections of synthetic small molecules, natural products, or extracts within chemical libraries to pinpoint substances exhibiting beneficial therapeutic effects. This method is to first discover the in vivo or in vitro functional activity of drugs (such as extract drugs or natural products), and then perform target identification. Phenotypic discovery uses a practical and target-independent approach to generate initial leads, aiming to discover pharmacologically active compounds and therapeutics that operate through novel drug mechanisms. This method allows the exploration of disease phenotypes to find potential treatments for conditions with unknown, complex, or multifactorial origins, where the understanding of molecular targets is insufficient for effective intervention.

== Advantages == EC-MS is a sensitive ionization method. Forming negative ions through electron capture ionization is more sensitive than forming positive ions through chemical ionization. It is a selective ionization technique that can prevent the formation of common matrices found in environmental contaminants during ionization. Electron capture ionization will have less interference from these matrices compared to electron ionization. Electron capture mass spectra can distinguish between certain isomers that EI-MS cannot.

If the temperature is decreased, the metabolic activity in the fish from microbial or autolytic processes can be reduced or stopped. This is achieved by refrigeration where the temperature is dropped to about 0 °C, or freezing where the temperature is dropped below -18 °C. On fishing vessels, the fish are refrigerated mechanically by circulating cold air or by packing the fish in boxes with ice. Forage fish, which are often caught in large numbers, are usually chilled with refrigerated or chilled seawater. Once chilled or frozen, the fish need further cooling to maintain the low temperature. There are key issues with fish cold store design and management, such as how large and energy efficient they are, and the way they are insulated and palletized. An effective method of preserving the freshness of fish is to chill with ice by distributing ice uniformly around the fish. It is a safe cooling method that keeps the fish moist and in an easily stored form suitable for transport. It has become widely used since the development of mechanical refrigeration, which makes ice easy and cheap to produce. Ice is produced in various shapes; crushed ice and Flake Ice, plates, tubes and blocks are commonly used to cool fish. Particularly effective is slurry ice, made from micro crystals of ice formed and suspended within a solution of water and a freezing point depressant, such as common salt. A more recent development is pumpable ice technology.

=== Infrared ear thermometers === Diatek Corporation and NASA developed an aural thermometer that measures the thermal radiation emitted by the eardrum, similar to the way the temperature of stars and planets are measured. This method avoids contact with mucous membranes and permits rapid temperature measurement of newborn or incapacitated patients. NASA supported the Diatek Corporation through the Technology Affiliates Program.

Sources: en.wikipedia.org

Further detail

Certain countries adopt immigration policies designed to be favourable towards members of diaspora communities with a connection to the country. For example, the Indian government confers Overseas Citizenship of India (OCI) status on foreign citizens of Indian origin to enable them to live and work indefinitely in India. OCI status was introduced in response to demands for dual citizenship by the Indian diaspora, particularly in countries with large populations of Indian origin. It was introduced by The Citizenship (Amendment) Act, 2005 in August 2005. Similar to OCI status, the UK Ancestry visa exempts members of the British diaspora from usual immigration controls. Poland issued the Karta Polaka to citizens of certain northeast European countries with Polish ancestry, but later expanded it to the worldwide Polonia. Some nations recognise a right of return for people with ancestry in that country or a connection to a particular ethnic group. A notable example of this is the right of Sephardi Jews to acquire Spanish nationality by virtue of their community's Spanish origins. Similar exemptions to immigration controls exist for people of Armenian origin seeking to acquire Armenian citizenship. Ghana similarly grants an indefinite right to stay in Ghana to members of the African diaspora, regardless of citizenship. Similarly, Israel maintains a policy permitting members of the Jewish diaspora to immigrate to Israel regardless of prior nationality.

But severe indoor air quality conditions also can emerge in affluent, highly-developed locales; for example, children fell sick from indoor mold in an apartment complex in Riviera Beach, Florida. Typically, poor indoor air quality is often related to cooking and heating methods by burning biomass fuel, in the form of wood, charcoal, dung, and crop residue, in indoor environments that lack proper ventilation. Millions of people, primarily women and children, face serious health risks. In total, about three billion people in developing countries are affected by this problem. The World Health Organization (WHO) estimates that cooking-related indoor air pollution causes 3.8 million annual deaths. The Global Burden of Disease study estimated the number of deaths in 2017 at 1.6 million.

== History == A digital ion trap (DIT) is an ion trap having a trapping waveform generated by the rapid switching between discrete high-voltage levels. The timing of the high voltage switch is controlled precisely with digital electronic circuitry. Ion motion in a quadrupole ion trap driven by a rectangular wave signal was theoretically studied in 1970s by Sheretov, E.P. and Richards, J.A. Sheretov also implemented the pulsed waveform drive for the quadrupole ion trap working in mass-selective instability mode, although no resonance excitation/ejection was used. The idea was substantially revisited by Ding L. and Kumashiro S. in 1999, where the ion stability in the rectangular wave quadrupole field was mapped in the Mathieu space a-q coordinate system, with the parameters a and q having the same definition as the Mathieu parameters normally used in dealing with sinusoidal RF driven quadrupole field. The secular frequency dependence on the a, q parameters was also derived thus the foundation was laid for many modern ion trap operation modes based on the resonance excitation. Also, in 1999, Peter T.A. Reilly began trapping and subsequently ablating and mass analyzing the product ions from nanoparticles obtained from car exhaust with a primitive hybrid square wave/sine wave driven 3D ion trap. In 2001 Reilly attended the 49th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Applied Topics where he presented his nanoparticle mass analysis work and met Li Ding for the first time.

Immediate antibody-mediated allergic reactions (wheals) have been elicited in infected persons, but not in those not infected; immediate hypersensitivity of this type is thought to explain the observed far more rapid allergic skin response to reinfection seen in persons who have been infected previously, especially within the previous year or two.

Sources: en.wikipedia.org

Frequently asked questions

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

What do researchers measure after administering the peptide?

Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.

Are the clinical effects well established?

Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.

What is the difference between the forms with and without a drug affinity complex?

The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.

Network